Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.34 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.34 |
| ▸ | ITGAL | P20701 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | EED | O75530 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29805110 | 1.00 | PDCD1 (0.39) | PDCD1CD274MTNR1AADRA2AADRA2C | |
| SCHEMBL22131594 | 0.83 | TAAR1 (0.41) | MTNR1AADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL5248739 | 0.77 | ITGB2 (0.38) | MTNR1AADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL30641376 | 0.73 | ADRA2A (0.40) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL20756201 | 0.73 | ADRA2A (0.40) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL16404623 | 0.73 | MAPT (0.43) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL3115776 | 0.73 | ALDH1A1 (0.44) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL15202099 | 0.73 | FABP6 (0.40) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL30343091 | 0.73 | ITGB2 (0.38) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL979462 | 0.73 | ITGB2 (0.38) | ADRA2AADRA2CADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1428514-B1 | Dyeing composition comprising a tertiary paraphenylenediamine containing a pyrrolidine, a tertiary paraphenylenediamine and a benzomorpholine coupler; method and use | OREAL (FR) | 2007-09-19 | — | — | EP | claimed |
| EP-1428514-A1 | Dyeing composition comprising a tertiary paraphenylenediamine containing a pyrrolidine, a tertiary paraphenylenediamine and a benzomorpholine coupler; method and use | L'OREAL (FR) | 2004-06-16 | — | — | EP | claimed |
| CN-114828959-B | 3- (5-methoxy-1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivative and application thereof | 诺华股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| EP-4076650-B1 | 3-(5-METHOXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2024-02-28 | — | — | EP | disclosed |
| EP-4076650-B1 | 3-(5-METHOXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2024-02-28 | — | — | EP | disclosed |
| US-11566022-B2 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2023-01-31 | — | — | US | disclosed |
| US-11566022-B2 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2023-01-31 | — | — | US | disclosed |
| US-20220402904-A1 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof | NOVARTIS AG (CH) | 2022-12-22 | — | — | US | disclosed |
| US-20220402904-A1 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof | NOVARTIS AG (CH) | 2022-12-22 | — | — | US | disclosed |
| CN-114828959-A | 3- (5-methoxy-1-oxoisoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof | 诺华股份有限公司 | 2022-07-29 | — | — | CN | disclosed |
| WO-2021124172-A1 | 3-(5-METHOXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021124172-A1 | 3-(5-METHOXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2021-06-24 | — | — | WO | disclosed |
| WO-2015066371-A1 | SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS | FORUM PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | WO | disclosed |
| EP-1428514-B1 | Dyeing composition comprising a tertiary paraphenylenediamine containing a pyrrolidine, a tertiary paraphenylenediamine and a benzomorpholine coupler; method and use | OREAL (FR) | 2007-09-19 | — | — | EP | disclosed |
| EP-1428514-A1 | Dyeing composition comprising a tertiary paraphenylenediamine containing a pyrrolidine, a tertiary paraphenylenediamine and a benzomorpholine coupler; method and use | L'OREAL (FR) | 2004-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566022-B2 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | HBZ, ZFX, HBG1 | PDCD1 2253/4885CD274 3607/4885MTNR1A 3153/4885 |
| US-20220402904-A1 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof | HBZ, ZFX, HBG1 | PDCD1 2236/4885CD274 3563/4885MTNR1A 3079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.